Skip to Content
Merck
  • Acute and Repeated Treatment with 5-PAHSA or 9-PAHSA Isomers Does Not Improve Glucose Control in Mice.

Acute and Repeated Treatment with 5-PAHSA or 9-PAHSA Isomers Does Not Improve Glucose Control in Mice.

Cell metabolism (2018-06-26)
Elsa Pflimlin, Maximilian Bielohuby, Marcus Korn, Kristin Breitschopf, Matthias Löhn, Paulus Wohlfart, Anish Konkar, Michael Podeschwa, Felix Bärenz, Anja Pfenninger, Uwe Schwahn, Till Opatz, Marcel Reimann, Stefan Petry, Norbert Tennagels
ABSTRACT

Fatty acid esters of hydroxylated fatty acids (FAHFAs) were discovered as a novel class of endogenous mammalian lipids whose profound effects on metabolism have been shown. In the current study, in vitro and in vivo the metabolic effects of two of these FAHFAs, namely palmitic acid-5- (or -9) -hydroxy-stearic acid (5- or 9-PAHSA, respectively) were profiled. In DIO mice fed with differentially composed low- or high-fat diets, acute and subchronic treatment with 5-PAHSA and 9-PAHSA alone, or in combination, did not significantly improve the deranged metabolic status. Neither racemic 5- or 9-PAHSA, nor the enantiomers were able to: (1) increase basal or insulin-stimulated glucose uptake in vitro, (2) stimulate GLP-1 release from GLUTag cells, or (3) induce GSIS in rat, mouse, or human islets or in a human pancreatic β cell line. Therefore, our data do not support the further development of PAHSAs or their derivatives for the control of insulin resistance and hyperglycemia.

MATERIALS
Product Number
Brand
Product Description

Avanti
9-PAHSA-d9, Avanti Research - A Croda Brand 860409C
Avanti
18:1 Lyso PA, Avanti Research - A Croda Brand
Avanti
5-PAHSA-d9, Avanti Research - A Croda Brand 860410C